Hormonal, Metabolic, and Signaling Interactions in PAH

Recruiting now

Conditions studied: Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH

In brief

Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.

Key facts

Study ID: NCT01884051
Run by: Vanderbilt University Medical Center
People needed: 1899
Starts: 2012-09-01
Expected to finish: 2032-07-01
Last updated by the study team: 2025-09-16

Who can join

Age: any, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Project 1
Inclusion:
Diagnosis of IPAH (idiopathic pulmonary arterial hypertension), HPAH (heritable pulmonary arterial hypertension), or APAH (associated pulmonary arterial hypertension), family members of affected persons
Age 0-90, age 12-90 for skin biopsy
Exclusion:
Other diagnosis
Age greater than 90, age less than 12 or greater than 90 for skin biopsy
Project 2
Inclusion:
Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
0-90
Subjects with reasonably easy access to clinic for blood collection and other testing
Subject able to tolerate fasting state prior to sample collection and EndoPAT (endothelial function assessment) testing
Exclusion:
Other diagnosis
0-90
Subjects with difficulty reaching clinic for blood collection and other testing
Subjects unable to tolerate fasting state
Project 3
Inclusion:
Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
7-90
Exclusion:
Other diagnosis
Age less than 7 or greater than 90

Where it is running

Vanderbilt University Medical Center — Nashville, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.